Scripps Research Logo

The Thomas Lab


Mirendil, H., Thomas, E.A., De Leora, C., Okada, K., Inomata, Y., Chun, J. LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage. Translational Psychiatry 5: e541 (2015).

Jia, H., Morris, C.D., Williams, R., Loring, J.F., Thomas, E.A. Histone deacetylase inhibition imparts beneficial transgenerational epigenetic effects in Huntington's disease transgenic mice via alterations in DNA and histone methylation. Proc. Natl. Acad. Sci. USA 112(1):E56-64 (2015).

Corey-Bloom, J., Jia, H., Aikin,  A.M., Thomas, E.A.  Disease modifying potential of glatiramer acetate in Huntington's disease.  Journal of Huntington’s Disease, 3:311–316 (2014).

Thomas, E. A. Involvement of HDAC1 and HDAC3 in the pathology of polyglutamine disorders: therapeutic implications for selective HDAC1/HDAC3 inhibitors.  Pharmaceuticals 7:634-661 (2014).

Unterwald, E.M., Page, M.E., Brown, T.B., Miller, J.S., Ruiz, M., Pescatore, K.A., Xu, B., Reichardt, L.F., Beverley, J., Tang, B., Steiner, H., Thomas, E.A., Ehrlich, M.E.  Behavioral and transcriptome alterations in male and female mice with postnatal deletion of TrkB in dorsal striatal medium spiny neurons.  Molecular Neurodegeneration 8:47 (2013).

Tang, B, Jia, H., Kast, R. J., Thomas, E. A.  Epigenetic changes at gene promoters in response to immune activation in utero.  Brain, Behavior and Immunity. 30:168-75 (2013).

Jia, H., Kast, R. J., Steffan, J. S., Thomas, E. A.  Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington’s disease mice; implications for the ubiquitin–proteasomal and autophagy systems.  Human Molecular Genetics, 21:5280-93 (2012).

Tang, B., Becanovic, K., Desplats, P.A., Spencer, B., Hill, A.M., Connolly, C., Masliah, E., Leavitt, B.R., Thomas, E.A.  Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS; implications for transcriptional dysregulation in Huntington disease.  Human Molecular Genetics, 21:3097-111 (2012).

Jia, H., Pallos, J, Jacques, V., Lau, A., Tang, B., Cooper, A., Syed, A., Purcell, J., Chen, Y., Sharma, S., Sangrey, G.R., Darnell, S.B., Plasterer, H., Sadri-Vakili, G., Gottesfeld, J.M., Thompson, L.M., Rusche, J.R.,  Marsh, J.L., Thomas, E.A.  Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.  Neurobiology of Disease, 46:351-61 (2012).

Thomas, E.A. Transcriptomics of antipsychotic drug function: What have we learned from rodent studies?  Current Psychopharmacology, 1(4):272-283 (2012).

Keilani, S., Chandwani, S., Dolios, G., Beck, H., Hatzopoulos, A., Rao, G., Thomas, E.A. Wang, R., Ehrlich, M.E.  Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element.  Journal of Neuroscience, 32:6808-6818 (2012).

Tang, B., Dean, B., Thomas, E.A.  Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders.  Translational Psychiatry, 1: e64 (2011). * this article was the #1 downloaded article for Translational Psychiatry in January 2012.

Tang, B., Capitao, C., Dean, B., Thomas, E.A.  Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia.  Psychiatry Research, 196:201-6 (2012).

Tang, B., Dean, B., Thomas, E.A. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Translational Psychiatry, 1: e64 (2011). * this article was the #1 downloaded article for Translational Psychiatry in January 2011.

Tang, B., Capitao, C., Dean, B., Thomas, E.A. Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Research, In Press.

Tang, B., Di Lena, P., Schaffer, L., Head, S.R., Thomas, E.A. Genome-wide identification of Bcl11b gene targets reveals role in brain-derived neurotrophic factor signaling. PLoS ONE 6(9):e23691 (2011).

Tang, B., Seredenina, T., Coppola, G., Kuhn, A., Geschwind, D.H., Luthi-Carter, R., Thomas, E.A. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease Neurobiology of Disease 42(3):459-67 (2011).

Thomas, E.A., Coppola, G., Tang, B., Kuhn, A., Kim, S., Geschwind, D.H., Brown, T.B., Luthi-Carter, R., Ehrlich, M.E. In Vivo Cell-autonomous Transcriptional Abnormalities Revealed in Mice Expressing Forebrain Striatal-restricted Mutant Huntingtin. Human Molecular Genetics, 20(6):1049-60 (2011). * this article was featured on the cover.

Sutcliffe, J.G., Hedlund, P., Thomas, E.A., Bloom, F., Hilbush, B. Peripheral reduction of β-amyloid is sufficient to reduce brain Aβ: implications for Alzheimer's disease. Journal of Neuroscience Research. 89(6):808-14 (2011).

Narayan, S., Thomas E.A. Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology? Frontiers in Bioscience16:1797-810 (2011).

Ku, S., Soragni, E., Campau, E., Thomas, E.A., Altun, G., Laurent, L.C., Loring, J.F., Napierala, M., Gottesfeld, J.M. Friedreich's Ataxia Induced Pluripotent Stem cells Model Intergenerational GAA*TTC Triplet-Repeat Instability. Cell Stem Cell 7(5):631-7 (2010).

Denny, C.A., Desplats, P.A., Thomas, E.A., Seyfried, T.N. Cerebellar Lipid Differences between R6/1 Transgenic Mice and Humans with Huntington's Disease. Journal of Neurochemistry 115(3):748-58 (2010).

Schlosburg, J.E., Blankman, J.L., Long, J.Z., Nomura, D.K., Pan, B., Kinsey, S.G., Nguyen, P.T., Ramesh, D., Booker, L., Burston, J.J., Thomas, E.A., Selley, D.E., Sim-Selley, L.J., Liu, Q.S., Lichtman, A.H., Cravatt, B.F. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci. 13:1113-9 (2010).

Udewala M., Gibbons A., Hannan, A. Thomas, E.A., Scarr, E., Dean, B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. ANZ Journal of Psychiatry, 2010 Nov 23.

Torkamani, A., Dean, B., Schork, N.J., Thomas, E.A. Co-Expression Network Analysis of Neural Tissue Reveals Perturbations in Developmental Processes in Schizophrenia. Genome Research, 20:403-12 (2010). * this article was featured on the cover.

Perdomo, G., Kim, D.H., Zhang, T., Qu, S., Thomas, E.A., Toledo, F.G.S., Slusher, S., Fan, Y., Kelley, D.E., Dong, H. A Role of Apolipoprotein D in Triglyceride Metabolism. Journal of Lipid Research, 51:1298-311 (2010).

Gibbons, A.S., Thomas, E.A., Dean, B. Regional and Duration of Illness Differences in NCAM-180 mRNA Expression within the Cortex of Subjects with Schizophrenia. Schiz. Res. 112:65-71 (2009)

Thomas, E.A. Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors. Molecular Neurobiology. 40:33-45 (2009).

Tang, B., Chang, W., Lanigan, C.M., Dean, B., Sutcliffe J.G., Thomas, E.A. Normal Human Aging and Early- Stage Schizophrenia Share Common Molecular Profiles. Aging Cell 8:339-42 (2009).

Thomas, E.A. Selective HDAC Inhibitors: Promising Treatment for Huntington's Disease. Bioforum Europe 13:32-34 (2009).

Thomas, E.A., Coppola, G., Desplats, P.A. Tang, B., Soragni, E. Burnett, R., Gao, F., Fitzgerald, K.M., Borok, J.F., Herman, D., Geschwind, D. H., Gottesfeld, J.M. The Histone Deacetylase Inhibitor, HDACi 4b, Ameliorates the Disease Phenotype and Transcriptional Abnormalities in Huntington's Disease Transgenic Mice. Proc. Natl. Acad. Sci. USA, 105:15564-9 (2008).

Thomas, E.A. Striatal Specificity of Gene Expression Dysregulation in Huntington's Disease. Journal of Neuroscience Research 84:1151-1164 (2006).

Narayan, S., Tang, B., Steven Head, S.R., Gilmartin, T.J., Sutcliffe, J.G., Dean, B. and Thomas, E.A. Molecular Profiles of Schizophrenia in the CNS at Different Stages of Illness. Brain Res. 1239:235-248 (2008).

Narayan, S., Head, S.R., Gilmartin, T.J., Dean, B. and Thomas, E.A. Evidence for Disruption of Sphingolipid Metabolism in Schizophrenia. Journal of Neuroscience Research. 87:278-288 (2009).

Desplats, P.A., Lambert, J.R. and Thomas, E.A. Functional Roles for the Striatal-Enriched Transcription Factor, Bcl11b, in the Control of Striatal Gene Expression and Transcriptional Dysregulation in Huntington's Disease. Neurobiology of Disease 31:298-308 (2008).

Gibbons, A. S., Scarr, E., McOmish, C., Hannan, A.J., Thomas, E.A., Dean, B. RGS4 expression is not altered in the prefrontal cortex of schizophrenics. ANZ Journal of Psychiatry, 42:740-5 (2008).

Dean, B., Digney, A., Sundram, S., Thomas, E.A. and Scarr, E. Plasma Apolipoprotein E is Decreased in Schizophrenia Spectrum and Bipolar Disorder. Psychiatry Research 158:75-78 (2008).

Desplats, P.A., Denny, C.A., Kass, K.E., Gilmartin, T., Head, S.R., Sutcliffe, J.G., Seyfried, T.N. and Thomas, E.A. Glycolipid and Ganglioside Metabolism Imbalances in Huntington's Disease. Neurobiology of Disease 27:265-77 (2007).

Dean, B., Keriakous, B., Scarr, E., Thomas, E.A. Gene Expression Profiling in Brodmann's Area 46 from Subjects with Schizophrenia. ANZ Journal of Psychiatry 41:308-320 (2007).

Narayan, S., Kass, K.E. and Thomas, E.A. Chronic Haloperidol Treatment Results in a Decrease in the Expression of Myelin/Oligodendrocyte-Related Genes in the Mouse Brain. Journal of Neuroscience Research 85:757-65 (2007).

Thomas, E.A. and Yao, J.K. Clozapine Specifically Alters the Arachidonic Acid Pathway in Mice Lacking Apolipoprotein D. Schizophrenia Research 89:147-53 (2007).

Thomas, E.A. Molecular Profiling of Antipsychotic Drug Function: Convergent Mechanisms in the Pathology and Treatment of Psychiatric Disorders. Molecular Neurobiology 34:109-28 (2006).

Desplats, P.A., Kass, K. E., Gilmartin, T., Stanwood, G.D., Head, S.H., Sutcliffe, J.G. Thomas. E.A. Selective Deficits in the Expression of Striatal-Enriched mRNAs in Huntington's Disease. Journal of Neurochemistry 96:743-757 (2006).

Ziolkowska, B., Bilecki, W., Gieryk, A., Danielson, P.E., Thomas, E.A., Hilbush, B.S., Sutcliffe, J.G., Przewlocki, R. Regulation of alpha-synuclein expression in limbic and motor brain regions of morphine-treated mice. Journal of Neuroscience 25:4996-5003 (2005).

Digney, A., Keriakous, D., Scarr, E., Thomas, E.A., Dean, B. Differential Changes in ApoE in Schizophrenia and Bipolar Disorder Type I. Biological Psychiatry 57:711-715 (2005).

Dean, B., Keriakous, D., Thomas, E.A. and Scarr, E. Understanding the Pathology of Schizophrenia: The Impact of High-Throughput Screening of the Genome and Proteome in Postmortem CNS. Current Psychiatry Reviews 1:1-9 (2005).

Yao, J.K., Thomas, E.A., Reddy, R.D., Keshavan, M.S. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophrenia Research. 72:259-266 (2005).

Thomas, E.A., George, R.C., Danielson, P.E., Nelson, P.A., Warren, A.J., Lo, D. and J.G. Sutcliffe. Antipsychotic Drug Treatment Alters Expression of mRNAs Encoding Lipid Metabolism-Related Proteins. Molecular Psychiatry 8:983-993 (2003).

Thomas, E.A., George, R. C. and J.G. Sutcliffe. Apolipoprotein D Modulates Arachidonic Acid Signaling in Cultured Cells: Implications for Psychiatric Disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids 69:421-427 (2003).

Thomas, E.A., Copolov, D.L. and J.G. Sutcliffe. From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders. Current Molecular Medicine 3:408-18 (2003).

Thomas, E.A., Laws, S.M., Sutcliffe, J. G, Harper, C., Dean, B., McClean, C., Masters, C., Lautenschlager, N., Gandy, S. E., and R. N. Martins. Apolipoprotein D Levels are Elevated in Prefrontal Cortex of Subjects with Alzheimer's Disease: No Relation to Apolipoprotein E Expression or Genotype. Biological Psychiatry 54:136-141 (2003).

Dean, B., Laws, S.M., Hone, E., Taddei, K. Scarr, E., Thomas, E.A., Harper, C., McClean, C. Masters, C., Lautenschlager, N., Gandy, S.E. and R.N. Martins. Increased levels of apolipoprotein E in the frontal cortex from subjects with schizophrenia. Biological Psychiatry 54:616-622 (2003).

Thomas, E.A., Dean, B., Scarr, E., Pavey, G., Copolov, D. and J.G. Sutcliffe. Differences in Neuroanatomical Sites of ApoD Elevation Discriminate between Schizophrenia and Bipolar Disorder. Molecular Psychiatry 8:167-175 (2003).

Hedlund, P.B., Danielson, P.E., Thomas, E.A., Slanina, K., Carson, M.J. and J.G. Sutcliffe. No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc. Natl. Acad. Sci. USA 100:1375-1380 (2003).

Thomas, E.A. and J.G. Sutcliffe. The neurobiology of apolipoproteins in psychiatric disorders. Molecular Neurobiology 26:369-88 (2002).

Alvarez, C.E., Sutcliffe, J.G. and E.A. Thomas. Novel Isoform of IRSp53 is Generated by Alternative Splicing in the CRIB/SH3-binding Region. Journal of Biological. Chemistry 277:24728-34 (2002).

Nelson, P.A., Sutcliffe, J.G. and E.A. Thomas. A New UDP-GalNAc:Polypeptide N-acetylgalactosaminyltransferase mRNA Exhibits Predominant Expression in Mouse Hypothalamus, Thalamus and Amygdala in Mouse Forebrain. Gene Expression Patterns 1:95-99 (2002).

Thomas, E.A., Sautkulis, L. N., Criado, J.R., Games, D. and J.G. Sutcliffe. Apolipoprotein D mRNA Expression is Elevated in PDAPP Transgenic Mice. Journal of Neurochemistry 79:1059-1064 (2001).

Thomas, E.A., Foye, P.E., Alvarez, C. E., Usui, H. and J.G. Sutcliffe. Insulin receptor substrate protein p53 localization suggests mechanism for specific neurodegeneration in rats. Neuroscience Letters 309:145-148 (2001).

Thomas, E.A., Dean, B. and J.G. Sutcliffe. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: Implications for the pathophysiology of psychiatric disorders. Proc. Natl. Acad. Sci. USA 98:4066-4071 (2001).

Thomas, E.A., Danielson, P.E., Nelson, P. A., Pribyl, T. M., Hilbush, B. S., Hasel, K. W. an d J.G. Sutcliffe. Clozapine Increases Apolipoprotein D Expression in Rodent Brain: Towards a Mechanism for Neuroleptic Pharmacotherapy. Jorunal of Neurochemistry 76:778-788 (2001).

Thomas, E.A., Matli, J. R., Hu, J.L., Carson, M.J. and J.G. Sutcliffe. Pertussis Toxin Treatment Prevents 5-HT5a Receptor-Mediated Inhibition of Cyclic AMP Accumulation in Rat c6 Glioma Cells. Journal of Neuroscience Research. 61:75-81 (2000).

Thomas, E.A., Alvarez, C.E. and J.G. Sutcliffe. Evolutionarily Distinct Classes of S27 Ribosomal Proteins with Differential mRNA Expression in Rat Hypothalamus. Journal of Neurochemistry 74:2259-2267 (2000).

Hedlund, P.B., Carson, M.J., Sutcliffe, J.G. and E.A. Thomas. Allosteric Regulation by Oleamide of the Binding Properties of 5-Hydroxytryptamine7 Receptors. Biochemical Pharmacology 58:1807-1813 (1999).

Thomas, E.A., Cravatt, B.F. and J.G. Sutcliffe. The Endogenous Lipid Oleamide Activates 5HT7 Neurons in Mouse Thalamus and Hypothalamus. Journal of Neurochemistry 72:2370-2378 (1999).

Thomas, E.A., Carson, M.J. and J.G. Sutcliffe. Oleamide-Induced Modulation of 5-Hydroxytryptamine Receptor-Mediated Signaling. New York Acad. Sci. 861:183-189 (1998).

Thomas, E.A., Danielson, P.E. and J.G. Sutcliffe. RGS9: A Regulator of G-Protein Signalling with Specific Expression in Rat and Mouse Striatum. Journal of Neuroscience Research 52:118-124 (1998).

Thomas, E.A., Carson, M.J., Neal M.J. and J.G. Sutcliffe. Unique Allosteric Regulation of 5HT Receptor-Mediated Signal Transduction by Oleamide. Proc. Natl. Acad. Sci. USA 94:14115-14119 (1997).

Thomas, E.A., Cravatt, B.F., Danielson, P.E., Gilula, N.B. and J.G. Sutcliffe. Fatty Acid Amide Hydrolase (FAAH), the Degradative Enzyme for Neuromodulatory Fatty Acid Amides, Has Widespread Distribution in Neurons within the Rat Central Nervous System. Journal of Neuroscience Research 50:1047-1052 (1997).

Carson, M.J., Thomas, E.A., Danielson P.E. and J.G. Sutcliffe. The 5HT5a Serotonin Receptor is Expressed Predominantly by Astrocytes in Which it Inhibits cAMP Accumulation: A Mechanism for Neuronal Suppression of Reactive Astrocytes. Glia 17:317-326 (1996).

Thomas, E.A. and F.J. Ehlert. Involvement of the M2 Muscarinic Receptor in Contraction of the Guinea Pig Trachea, Guinea Pig Esophagus and Rat Fundus. Biochemical Pharmacology 51:779-788 (1996).





Group Members




Contact Us